The influence of a direct renin inhibitor on the central blood pressure

Journal of Nippon Medical School

Volumn 80, Issue 1, 2013, Pages 25-33

  Kubota, Yoshiaki ^a   Takahashi, Hiroshi ^a   Asai, Kuniya ^a   Yasutake, Masahiro ^a   Mizuno, Kyoichi ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Augmentation index; Central blood pressure; Direct renin inhibitor

Indexed keywords

ALBUMIN; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; CREATININE; HYDROCHLOROTHIAZIDE; RENIN INHIBITOR;

ADULT; ARTICLE; AUGMENTATION INDEX; BLOOD PRESSURE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SENSITIVITY; DYSLIPIDEMIA; FOLLOW UP; HUMAN; HYPERTENSION; IMMUNOASSAY; INFLAMMATION; MICROALBUMINURIA; PHYSIOLOGICAL PROCESS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SYSTOLIC BLOOD PRESSURE;

ADULT; AMIDES; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; FUMARATES; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; PROSPECTIVE STUDIES; RENIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84874100744     PISSN: 13454676     EISSN: 13473409     Source Type: Journal    
DOI: 10.1272/jnms.80.25     Document Type: Article

References (30)

1. Williams B, Lacy PS, Thorn SM, et al.: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113: 1213-1225.
2. Chen CH, Nevo E, Fetics B, et al.: Estimation of central aortic pressure waveform by mathematical transformation of radial tonometry pressure. Validation of generalized transfer function. Circulation 1997; 95: 1827-1836.
3. Takazawa K, Kobayashi H, Shindo N, et al.: Relationship between radial and central arterial pulse wave and evaluation of central aortic pressure using the radial arterial pulse wave. Hypertens Res 2007; 30: 219-228.
4. Shimizu M, Kario K: Role of the augmentation index in hypertension. Ther Adv Cardiovasc Dis 2008; 2: 25-35.
5. Hashimoto J, Watabe D, Hatanaka R, et al.: Enhanced radial late systolic pressure augmentation in hypertensive patients with left ventricular hypertrophy. Am J Hypertens 2006; 19: 27-32.
6. Hashimoto J, Imai Y, O'Rourke MF: Indices of pulse wave analysis are better predictors of left ventricular mass reduction than cuff pressure. Am J Hypertens 2007; 20: 378-384.
7. Sakoda M, Ichihara A, Kurauchi-Mito A, et al.: Aliskiren inhibits intracellular angiotensin II levels without affecting (pro)renin receptor signals in human podocytes. Am J Hypertens 2010; 23: 575-580.
8. Morgan T, Lauri J, Bertram D, et al.: Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens 2004; 17: 118-123.
9. Miyashita H, Aizawa A, Hashimoto J, et al.: Cross-sectional characterization of all classes of antihypertensives in terms of central blood pressure in Japanese hypertensive patients. Am J Hypertens 2010; 23: 260-268.
10. Hatori N, Sato K, Miyakawa M, et al.: The current status of blood pressure control among patients with hypertension: a survey of actual clinical practice. J Nihon Med Sch 2012; 79: 69-78.
11. Kohara K, Tabara Y, Oshiumi A, et al.: Radial augmentation index: a useful and easily obtainable parameter for vascular aging. Am J Hypertens 2005; 18: 11S-14S.
12. Ding FH, Fan WX, Zhang RY, et al.: Validation of the noninvasive assessment of central blood pressure by the SphygmoCor and Omron devices against the invasive catheter measurement. Am J Hypertens 2011; 24: 1306-1311.
13. Sokolow M, Lyon TP: The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J 1949; 37: 161-186.
14. Mancia G, De Backer G, Dominiczak A, et al.: 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1462-1536.
15. Levey AS, Bosch JP, Lewis JB, et al.: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
16. Brown MJ, Mclnnes GT, Papst CC, et al.: Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet 2011; 377: 312-320.
17. Dinerman JL, Lowenstein CJ, Snyder SH: Molecular mechanisms of nitric oxide regulation. Potential relevance to cardiovascular disease. Circ Res 1993; 73: 217-222.
18. Guyenet PG: The sympathetic control of blood pressure. Nat Rev Neurosci 2006; 7: 335-346.
19. Hirooka Y, Sagara Y, Kishi T, et al: Oxidative stress and central cardiovascular regulation. - Pathogenesis of hypertension and therapeutic aspects. Circ J 2010; 74: 827-835.
20. Dong YF, Liu L, Kataoka K, et al: Aliskiren prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and type 2 diabetes. Diabetologia 2010; 53: 180-191.
21. Yamamoto E, Kataoka K, Dong YF, et al: Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice. Hypertension 2009; 54: 633-638.
22. Bakris GL, Ruilope L, Locatelli F, et al: Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int 2007; 72: 879-885.
23. Parving HH, Persson F, Lewis JB, et al: Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433-2446.
24. Parving HH, Persson F, Lewis JB, et al: [Aliskiren combined with losartan in type 2-diabetes and nephropathy - secondary publication]. Ugeskr Laeger 2009; 171: 881-884.
25. Utsumi K, Katsura K, lino Y, et al: Blood pressure control in patients with chronic kidney disease. J Nihon Med Sch 2012; 79: 111-114.
26. Fischer-Rasokat U, Brenck F, Zeiher AM, et al: Radial augmentation index unmasks premature coronary artery disease in younger males. Blood Press Monit 2009; 14: 59-67.
27. Takenaka T, Mimura T, Kanno Y, et al: Arterial wave reflection is elevated in evening hemodialysis patients. Clin Exp Hypertens 2008; 30: 173-181.
28. Solomon SD, Appelbaum E, Manning WJ, et al: Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009; 119: 530-537.
29. van Kats JP, Duncker DJ, Haitsma DB, et al: Angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade prevent cardiac remodeling in pigs after myocardial infarction: role of tissue angiotensin II. Circulation 2000; 102: 1556-1563.
30. van Esch JH, Moltzer E, van Veghel R, et al: Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats. J Hypertens 2010; 28: 2145-2155.